Zoledronic acid
- Generic Name
- Zoledronic acid
- Brand Names
- Aclasta, Reclast, Zometa, Zoledronic Acid Accord, Zoledronic acid Actavis, Zoledronic acid medac, Zoledronic acid Teva, Zoledronic Acid Hospira, Zoledronic acid Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C5H10N2O7P2
- CAS Number
- 118072-93-8
- Unique Ingredient Identifier
- 70HZ18PH24
- Background
Zoledronic acid, or CGP 42'446, is a third generation, nitrogen containing bisphosphonate similar to ibandronic acid, minodronic acid, and risedronic acid. Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone. Zoledronic acid ...
- Indication
Zoledronic acid is indicated to treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and Paget's disease of bone in men and women. Zoledronic acid is also indicated for the prevention of osteoporosis in post menopausal women and glucocorticoi...
- Associated Conditions
- Bone Metastases, Hypercalcemia of Malignancy, Multiple Myeloma (MM), Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Paget's Disease of Bone, Paget’s Disease
- Associated Therapies
- Bone Mineral Density
Duration of Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Men With Metastatic CRPC
- Conditions
- First Posted Date
- 2010-02-04
- Last Posted Date
- 2015-04-27
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 48
- Registration Number
- NCT01062503
- Locations
- 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada
Zoledronic Acid for the Prevention of Bone Loss Post-bone Marrow Transplantation for Thalassemia Major Patients
- Conditions
- Interventions
- First Posted Date
- 2009-11-18
- Last Posted Date
- 2011-07-26
- Lead Sponsor
- Tehran University of Medical Sciences
- Target Recruit Count
- 50
- Registration Number
- NCT01016093
- Locations
- 🇮🇷
Hematology-Oncology & SCT Research Center, Tehran, Iran, Islamic Republic of
Prevention of Micro-architectural Bone Decay in Males With Non-metastatic Prostate Cancer Receiving Androgen Deprivation Therapy (ADT)
- First Posted Date
- 2009-11-01
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- Austin Health
- Target Recruit Count
- 64
- Registration Number
- NCT01006395
- Locations
- 🇦🇺
Austin Health, Heidelberg, Victoria, Australia
Zometa Adjuvant Treatment of Malignant Pleural Effusion Due To Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-10-30
- Last Posted Date
- 2012-12-04
- Lead Sponsor
- Peter Bushunow MD
- Target Recruit Count
- 3
- Registration Number
- NCT01004510
- Locations
- 🇺🇸
Rochester General Hospital, Rochester, New York, United States
Study in Localized and Disseminated Ewing Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2009-10-01
- Last Posted Date
- 2019-10-22
- Lead Sponsor
- University Hospital Muenster
- Target Recruit Count
- 907
- Registration Number
- NCT00987636
- Locations
- 🇩🇪
University Hopital Essen, Pediatrics III, Hematology/ Oncology, Sarcoma Centre, International Ewing Sarcoma Study Group, West German Cancer Centre, Essen, Germany
🇩🇪University Children´s Hospital, Pediatric Hematology and Oncology, Muenster, Germany
Intra-venous Zoledronic Acid Once Yearly
- Conditions
- Interventions
- First Posted Date
- 2009-09-25
- Last Posted Date
- 2016-03-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1551
- Registration Number
- NCT00984893
- Locations
- 🇨🇦
Groupe de recherche en rhumatologie et maladies osseuses Inc, Quebec, Canada
An Efficacy and Safety Trial of Intravenous Zoledronic Acid in Infants Less Than One Year of Age, With Severe Osteogenesis Imperfecta
- First Posted Date
- 2009-09-22
- Last Posted Date
- 2016-04-19
- Lead Sponsor
- Shriners Hospitals for Children
- Target Recruit Count
- 14
- Registration Number
- NCT00982124
- Locations
- 🇨🇦
Shriners Hospital for Children, Montreal, Quebec, Canada
Effect of Combination of Bortezomib/Dexamethasone/Zoledronic Acid on Bone Disease in Patients With Multiple Myeloma Relapsed After 1-3 Prior Lines of Therapy
- Conditions
- Interventions
- First Posted Date
- 2009-09-09
- Last Posted Date
- 2014-08-05
- Lead Sponsor
- University of Athens
- Target Recruit Count
- 17
- Registration Number
- NCT00972959
- Locations
- 🇬🇷
Department of Clinical Therapeutics, University of Athens School of Medicine, "Alexandra" General Hospital, Athens, Greece
🇬🇷Department of Hematology, "Theagenion" Cancer Center, Thessaloniki, Greece
🇬🇷Department of Hematology & Medical Research, 251 General Air Force Hospital, Athens, Greece
Study of Zoledronic Acid Versus Observation on Bone Mineral Density and Incidence of Micrometastasis in Women Undergoing Pelvic Radiation for Cervical Cancer
- First Posted Date
- 2009-08-27
- Last Posted Date
- 2015-09-09
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 3
- Registration Number
- NCT00966992
- Locations
- 🇺🇸
Washington University, St. Louis, Missouri, United States
Effects of Teriparatide or Zoledronic Acid Treatment on Bone in Postmenopausal Osteoporotic Women
- Conditions
- Interventions
- First Posted Date
- 2009-06-24
- Last Posted Date
- 2013-04-04
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 69
- Registration Number
- NCT00927186
- Locations
- 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sainte-Foy, Quebec, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.